Norvasc Patent Still Invalid: Court
The U.S. Court of Appeals for the Federal Circuit denied Pfizer’s request for an en banc rehearing and left intact its previous ruling that found the pharmaceutical behemoth’s patent for Norvasc unenforceable. In so doing, the court granted Apotex’ request that it expedite its issuance of the decision.
The court’s previous ruling, handed down March...
To view the full article, register now.